Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CEPI And EU Grant Valneva $41.3M To Enhance Global Reach Of Chikungunya Vaccine IXCHIQ

Author: Benzinga Newsdesk | July 22, 2024 02:02am
  • Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®
  • Funding will support clinical trials in vulnerable groups, such as children and pregnant women
  • Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICs
  • IXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe

Posted In: VALN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist